- Home
- ORKA vs MREO Comparison
ORKA vs MREO Comparison
Compare ORKA & MREO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ORKA
- MREO
- Stock Information
- Founded
- ORKA 2004
- MREO 2015
- Country
- ORKA United States
- MREO United Kingdom
- Employees
- ORKA N/A
- MREO N/A
- Industry
- ORKA Biotechnology: In Vitro & In Vivo Diagnostic Substances
- MREO Biotechnology: Pharmaceutical Preparations
- Sector
- ORKA Health Care
- MREO Health Care
- Exchange
- ORKA Nasdaq
- MREO Nasdaq
- Market Cap
- ORKA 354.2M
- MREO 424.5M
- IPO Year
- ORKA N/A
- MREO N/A
- Fundamental
- Price
- ORKA $10.96
- MREO $2.15
- Analyst Decision
- ORKA Strong Buy
- MREO Strong Buy
- Analyst Count
- ORKA 8
- MREO 7
- Target Price
- ORKA $39.71
- MREO $7.71
- AVG Volume (30 Days)
- ORKA 143.0K
- MREO 943.2K
- Earning Date
- ORKA 05-14-2025
- MREO 05-13-2025
- Dividend Yield
- ORKA N/A
- MREO N/A
- EPS Growth
- ORKA N/A
- MREO N/A
- EPS
- ORKA N/A
- MREO N/A
- Revenue
- ORKA N/A
- MREO N/A
- Revenue This Year
- ORKA N/A
- MREO N/A
- Revenue Next Year
- ORKA N/A
- MREO $54.91
- P/E Ratio
- ORKA N/A
- MREO N/A
- Revenue Growth
- ORKA N/A
- MREO N/A
- 52 Week Low
- ORKA $5.49
- MREO $1.58
- 52 Week High
- ORKA $52.32
- MREO $5.02
- Technical
- Relative Strength Index (RSI)
- ORKA N/A
- MREO 40.94
- Support Level
- ORKA N/A
- MREO $2.12
- Resistance Level
- ORKA N/A
- MREO $2.27
- Average True Range (ATR)
- ORKA 0.00
- MREO 0.13
- MACD
- ORKA 0.00
- MREO -0.02
- Stochastic Oscillator
- ORKA 0.00
- MREO 9.09
About ORKA Oruka Therapeutics Inc. Common Stock
Oruka Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel monoclonal antibody therapeutics for psoriasis (PsO) and other inflammatory and immunology (I&I) indications. Its lead program, ORKA-001, is designed to target the p19 subunit of interleukin-23 (IL-23p19) for the treatment of PsO. The company's co-lead program, ORKA-002, is designed to target interleukin-17A and interleukin-17F (IL-17A/F) for the treatment of PsO, psoriatic arthritis (PsA), and other conditions. These programs each bind their respective targets at high affinity and incorporate half-life extension technology to increase exposure and decreasing dosing frequency.
About MREO Mereo BioPharma Group plc
Mereo BioPharma Group PLC is a United Kingdom (U.K.) based biopharmaceutical company focused on the development of therapeutics for rare diseases. The company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat primarily for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).